| BAY 16044 | An open-label phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumours known to express C4.4a | Hirte, Dr Hal | Open | NCT02134197 |
| GO29313 | A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | Hirte, Dr Hal | Open | NCT02219724 |
| IND.214 | A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours | Hotte, Dr Sebastien | Open | NCT02285816 |
| IND.226 | A PHASE IB STUDY OF DURVALUMAB (MEDI4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH ADVANCED INCURABLE SOLID MALIGNANCIES RECEIVING STANDARD CHEMOTHERAPY REGIMENS | Juergens, Dr Rosalyn | Open | NCT02537418 |
| IND.228 | A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours | Hirte, Dr Hal | Open | NCT02879162 |
| MDV3800-01 | A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal Impairment | Hirte, Dr Hal | Open | NCT02997163 |
| MDV3800-13 | A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib | Hirte, Dr Hal | Open | NCT02921919 |
Find a Trial
Contact Us